anti-mutant-EGFR antibodies (Aveo/Agios)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-mutant-EGFR antibodies (Aveo/Agios)
Drug Alias Name12D03
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAVEO Oncology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAVEO OncologyAgios Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A